Category

Europe Antibody Drug Conjugates Market Size, Share, And Trends By Target (CD 30, CD 22, HER 2), By Indication (Haematologic, Non-Haematologic Malignancies) And By Country - Forecast From 2019 To 2024

104 pages
Published on : Oct 2019
Report Code : KSI061613004

Related Reports

Description

The Europe antibody-drug conjugates (ADCs) market is expected to grow at a CAGR of 23.87% to reach a market size of USD2,421.585 million by the end of 2024. The market for antibody-drug conjugates is poised to grow at a rapid pace in the European region with the growing innovations in biotechnology leading to the formation of highly potent pharmaceutical drugs in the forecast period and in the coming years. Also, several companies based in this region are working on the development of highly potent ADCs for the cure of haematological and non-haematological malignancies. Furthermore, a high health expenditure of the European countries is further providing an opportunity for the market to grow in the forecast period with growing concern towards finding an effective cure for cancer patients in this region and at the global level. Moreover, the ability of ADCs to identify and eliminate the disease-associated cells is further gearing the growth of the development of ADCs with the growing incidences of cancer in this region.

The Europe antibody-drug conjugates market – Forecasts from 2019 to 2024 is an exhaustive study which aims to present the key market trends through various chapters focusing on different aspects of the market. The study provides a detailed market overview through the market dynamics sections which detail key market, drivers, restraints, and opportunities in the current market. The report analyzes key opportunity regional markets, and the current technology penetration through lifecycle analysis. The report also analyzes the market through comprehensive market segmentation by the target, by indication, and by country.

The Europe antibody-drug conjugates market on segmented based on target, indication, and country. Based on target the market has been segmented into CD 30, CD 22, and HER 2. By indication, the market is segmented into haematologic malignancies and non-haematologic malignancies.

Country-wise analysis has been provided with detailed analysis and forecast for the period 2018 to 2024, taking 2018 as the base year. The regional market has been broken down into the UK, Germany, France, and others. A thorough analysis and forecast have been done along with the prevailing market trends and opportunities which each of these countries presents for the manufacturers.

Major players in the Europe antibody-drug conjugates market have been covered along with their relative competitive position and strategies. The report also mentions recent deals and investments of different market players over the last year. The company profiles section details the business overview, financial performance for the past three years, key products and services being offered along with the recent developments of these important players in the Europe antibody-drug conjugates market.

Segmentation

The Europe antibody-drug conjugates market has been analyzed through the following segments:

By Target

CD 30

CD 22

HER 2

 

By Indication

Haematologic Malignancies

Non-Haematologic Malignancies

 

By Country

United Kingdom

Germany

France

Others

OUR CLIENTS